Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMPOWER A Single-arm, Phase III, Open Label, Multi-center, Study in Women Aged 18-35 Years of the Contraceptive Efficacy and Safety of AMPHORA® Contraceptive Vaginal Gel

Trial Profile

AMPOWER A Single-arm, Phase III, Open Label, Multi-center, Study in Women Aged 18-35 Years of the Contraceptive Efficacy and Safety of AMPHORA® Contraceptive Vaginal Gel

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2018

At a glance

  • Drugs Citric acid/lactic acid/potassium bitartrate (Primary)
  • Indications Pregnancy
  • Focus Registrational; Therapeutic Use
  • Acronyms AMPOWER
  • Sponsors Evofem Biosciences
  • Most Recent Events

    • 17 Dec 2018 According to an Evofem Biosciences media release, company will host a conference call to discuss the top-line data from this trial on December 17, 2018 at 8:30 a.m. EST.
    • 17 Dec 2018 According to an Evofem Biosciences media release, data from this trial, including an exploratory secondary endpoint of sexual satisfaction, will be submitted for presentation at upcoming scientific conferences and for publication in peer-reviewed journals following further analyses.
    • 17 Dec 2018 According to an Evofem Biosciences, primary endpoint ( Contraceptive efficacy ) has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top